Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming maart 2018

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,731   0,000   (0,00%) Dagrange 0,724 - 0,737 2.004.546   Gem. (3M) 4,9M

Pharming maart 2018

Volgen
20.968 Posts
Pagina: «« 1 ... 562 563 564 565 566 ... 1049 »» | Laatste | Omlaag ↓
  1. Pharmingbelegger2019 12 maart 2018 17:00
    quote:

    Techspec schreef op 12 maart 2018 16:44:

    [...]

    Ik denk dat Henk zich ook mateloos irriteert aan somige posters zoals mijns inziens Diegy en pfffff die het niveau van het forum weinig goeds doen doorvalleen maar te stangen, geen inhoudelijke reacties plaatsen en zo veel als mogelijke medeforum gebruikers op de kast proberen te jagen.

    Beste Henk,
    Kunt u hier AUB eens naar kijken en waar binnen de grenzen der mogelijkheden, hier iets aan doen.
    Dank u.
    MVG,
    Techspec....
    En toch is het met twee maten meten. Vanochtend vond u dat Antop gewoon door moet kunnen gaan met het posten van z’n positieve berichten UpUpUp naar de 1.75 op een reactie van mij op zijn nietszeggende berichten.
    Maar ook hij voegt toch helemaal niets toe op het Forum?

  6. [verwijderd] 12 maart 2018 17:02

    Buiten de mooie cijfers, afbouw schuldenlast, mooie prognoses....
    Hier nog maar eens waarom Pharming het aandeel van deze decade zal worden;

    Pipeline
    Expanding the pipeline beyond Ruconest®

    With validation secured from the approval of the first product from our transgenic platform, we will now seek to initiate new projects on this platform.

    Our transgenic platform remains the only technology that to date can deliver recombinant versions of certain complex human proteins in an economically viable way: this is a result of the low cost of capital investment required to start up a suitable founder herd, the fact that the herd is easily scalable and the high yield of product obtained.

    Our goal is to focus on indications that have a high unmet medical need using biologics to help patients that otherwise have limited choice in treatment.

    Expanding Beyond The Pipeline
    rhC1INH (Ruconest)

    Recombinant human C1 inhibitor (rhC1INH) is a recombinant human C1 inhibitor protein. Natural C1 inhibitor DNA from a human source is used in Pharming’s protein production technology to ensure expression of the C1 inhibitor protein. Human C1 inhibitor is a human plasma protein involved in the regulation of the complement and contact parts of the immune system. It is a controlling protein in early stages of these cascades and in that way a regulating factor of the immune system.
    By inhibiting these systems, the abnormal inflammation can be controlled. This is also the mechanism by which an HAE attack can be treated with C1 inhibitor.

    rhFVIII (Factor VIII)

    Recombinant human Factor VIII is a natural human blood clotting factor and is in early-stage development for treatment of Haemophilia A. Haemophilia A is a hereditary disorder caused by defects in the Factor VIII gene. Lack of functional Factor VIII diminishes the body’s clotting ability, which in turn can lead to damaging- or fatal bleeding episodes. On this project, Pharming has a service agreement with Renova Life to provide Pharming with founder rabbits.

    Haemophilia A is an X chromosome linked hereditary disorder caused by defects in the Factor VIII (FVIII) gene that lead to lower levels of the functional FVIII protein. Lack of functional FVIII diminishes the body’s clotting ability, which in turn can lead to damaging or fatal bleeding episodes.

    rhC1INH (Ruconest)
    Potential additional indications for Ruconest (rhC1INH) in development stage

    Recombinant human C1 inhibitor (rhC1INH) is a recombinant human C1 inhibitor protein. Natural C1 inhibitor DNA from a human source is used in Pharming’s protein production technology to ensure expression of the C1 inhibitor protein. Human C1 inhibitor is a human plasma protein involved in the regulation of the complement and contact parts of the immune system. It is a controlling protein in early stages of these cascades and in that way a regulating factor of the immune system. By inhibiting these systems, the abnormal inflammation can be controlled. This is also the mechanism by which an HAE attack can be treated with C1 inhibitor.

    Acute pancreatitis

    Acute pancreatitis (AP) is an acute inflammatory disorder of the pancreas for which there are currently no approved medical therapies. With approximately 300,000 hospitalizations per year (an increase of more than 2-fold since 1988), AP represents the single most frequent gastrointestinal cause of hospital admissions in the US.

    Based on the broad anti-inflammatory properties of C1INH, pdC1INH and rhC1INH have been studied in a variety of clinical conditions and animal models of numerous conditions involving contact and complement system activation with a vascular/capillary leak component. These studies have included models of pancreatitis, sepsis, thermal injury, xenotransplantation, and ischemia-reperfusion injury (e.g., myocardial infarction, stroke, delayed graft function in transplantation). Together, this experience suggests that rhC1INH may be able to interrupt the pro-inflammatory processes in patients with AP, and thereby resolve the ongoing SIRS to ultimately prevent organ failure.

    rhFVIII (Factor VIII)
    Factor VIII (rhFVIII)

    Haemophilia A is an X chromosome linked hereditary disorder caused by defects in the Factor VIII (FVIII) gene that lead to lower levels of the functional FVIII protein. Lack of functional FVIII diminishes the body’s clotting ability, which in turn can lead to damaging or fatal bleeding episodes.

    Recombinant human Factor VIII is a natural human blood clotting factor and is in early-stage development for treatment of Haemophilia A. Haemophilia A is a hereditary disorder caused by defects in the Factor VIII gene. Lack of functional Factor VIII diminishes the body’s clotting ability, which in turn can lead to damaging- or fatal bleeding episodes.

    As the first step in the assessment of develop-ability, Pharming signed a service agreement with Renova Life (RLI). The agreement covers the development and supply of founder transgenic rabbits from RLI to Pharming. The founder rabbits will enable Pharming to start the commercial production breeding process.

    Collaborative Product development: Strategic Collaborations with SIPI

    In addition recently we have entered a strategic collaboration for the development, manufacture and commercialisation of new products based on the Pharming technology platform with The Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Company based in China.

    sipi logo

    Under the terms of the agreement, Pharming will transfer the Pharming technology platform and manufacturing know- how to SIPI, such that joint global development for new products will take place at SIPI’s facilities in Shanghai and benefit from both the cost advantages of the Pharming platform and the competitive development and manufacturing costs structures at SIPI.

    The first projects to be jointly developed and manufactured at SIPI will be recombinant C1-inhibitor (conestat alfa) and Factor VIII.

    Products
    Ruconest EU_Flag

    Ruconest (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in the USA, Israel, all 28 EU countries plus Norway, Iceland and Liechtenstein.

    Ruconest is distributed in the EU by Swedish Orphan Biovitrum. Ruconest is partnered with Salix Pharmaceuticals Inc. in North America.

    Medical need

    C1 esterase inhibitor (C1INH) is a protein that naturally occurs in the human body. It belongs to the class of serine-protease inhibitors or serpins. It regulates several inflammatory pathways in the body by inhibiting certain proteins (proteases) that are part of the human immune system. Deficiency of functional C1 inhibitor leads to excessive activation of the complement system and other immunological and haemostatic pathways, giving cause to angioedema attacks. These attacks are characterized by acute and painful swellings of soft tissues. Administration of C1 inhibitor protein can normalize the low C1 INH levels and stop the angioedema attacks.

    Pharming’s therapy

    Patients who suffer from hereditary angioedema (HAE) have a deficiency of functional C1INH resulting from a mutation in the C1 inhibitor gene. For them, Pharming’s Ruconest provides a causal treatment with an excellent efficacy and safety profile. The GMP conform proprietary production and purification technology allows for the commercial manufacturing of large quantities of high-grade product of outstanding quality. Ruconest does not carry the risk of transmission of plasma related human infectious agents, as it is not isolated from human blood sources.
  19. ruud71 12 maart 2018 17:06
    quote:

    Diegy schreef op 12 maart 2018 17:00:

    Koers gaat naar day low betekent vaak niet vel goeds voor de volgende dag. Jullie zien toch ook dat er behoorlijk gedumpt word?
    Je kan ook schrijven dat je ze op dit moment niet hebt, maar lager wilt instappen en daarom negatieve berichten plaatst.
    Hoe laag staat jouw kooporder?
  20. [verwijderd] 12 maart 2018 17:08
    quote:

    Pharmingbelegger2018 schreef op 12 maart 2018 17:00:

    [...]

    En toch is het met twee maten meten. Vanochtend vond u dat Antop gewoon door moet kunnen gaan met het posten van z’n positieve berichten UpUpUp naar de 1.75 op een reactie van mij op zijn nietszeggende berichten.
    Maar ook hij voegt toch helemaal niets toe op het Forum?

    Er is een wezenlijk verschil en wel dat Antop het niveau van het forum niet verlaagt.

    Diegy en Pffff lijken eropuit te zijn om mensen constant op de kast te jagen.....
    Er zijn helaas teveel van dit soort posters die maar iets roepen....
20.968 Posts
Pagina: «« 1 ... 562 563 564 565 566 ... 1049 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Vertrek CEO overschaduwt goede resultaten Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: volop groeimotoren voor Pharming
  2. AEX opent waarschijnlijk hóger op Super Thursday met Besi, Unilever en Pharming
  3. Topman De Vries stopt bij Pharming
  4. Pharming start met Fase II klinische studie leniolisib
  5. Pharming: herstelpotentieel van 100%
  6. Slotcall: BAM en Pharming vinden gretig aftrek op groen gekleurd Damrak
  7. Micron-effect op de beurs? AEX gaat fraaie opening tegemoet, chipaandelen Azië vliegen
  8. Brits groen licht voor Joenja van Pharming
  9. Video: CEO tevreden over ontwikkelingen bij Pharming
  10. Dubbeltje op zijn kant voor AEX, terwijl cijferstorm aantrekt tot windkracht 10